Efficacy, Safety and Pharmacokinetics of Dolutegravir 50 Mg Once Daily with Food Versus Dolutegravir 50 Mg Twice Daily in HIV/TB Co-infected Patients Receiving Rifampin-based Antituberculosis Therapy
Latest Information Update: 08 Oct 2024
At a glance
- Drugs Dolutegravir (Primary)
- Indications HIV infections
- Focus Therapeutic Use
- 02 Oct 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.
- 02 Oct 2024 Planned primary completion date changed from 30 Jun 2024 to 30 Jun 2025.
- 27 Feb 2023 Planned End Date changed from 30 Jun 2022 to 30 Jun 2024.